| Identification | Back Directory | [Name]
SUBSTANCE P (6-11) | [CAS]
51165-07-2 | [Synonyms]
HEXA-SUBSTANCE P
6-11-Substance P
SUBSTANCE P (6-11)
[Gln6]substance P(6-11)
GLY-LEU-MET-NH2: GLM-NH2
SUBSTANCE P FRAGMENT 6-11)
GLN-PHE-PHE-GLY-LEU-MET-NH2
H-GLN-PHE-PHE-GLY-LEU-MET-NH2
SUBSTANCE-P-(-6-11) HEXA-SUBSTANCE P
L-Gln-L-Phe-L-Phe-Gly-L-Leu-L-Met-NH2
Substance P (6-11) H-Gln-Phe-Phe-Gly-Leu-Met-NH2 | [Molecular Formula]
C36H52N8O7S | [MDL Number]
MFCD00076797 | [MOL File]
51165-07-2.mol | [Molecular Weight]
740.91 |
| Hazard Information | Back Directory | [Uses]
Substance P (6-11) is the C-terminal hexapeptideamide of Substance P (Substance P (HY-P0201)). Substance P (6-11) binds to NK-1 tachykinin receptor. Substance P (6-11) shows depolarization of motoneurons and a hypotensive effect[1][2]. | [in vivo]
Substance P (6-11) (0.1-10 nM) inhibits insulin and glucagon secretion from the rat pancreas in a dose-dependent manner. In the canine pancreas, by contrast, Substance P (6-11) (1-10 nM), potentiates the release of insulin, glucagon, and somatostatin[2]. | [References]
[1] Y Torrens, et al. Substance P(6-11) and natural tachykinins interact with septide-sensitive tachykinin receptors coupled to a phospholipase C in the rat urinary bladder. Neuropeptides. 1997 Jun;31(3):243-51. DOI:10.1016/s0143-4179(97)90055-x
[2] Y Chiba, et al. Effects of substance P and substance P-(6-11) on hormone release from isolated perfused pancreas: their opposite actions on rat and canine islets. Endocrinology. 1985 Nov;117(5):1996-2000. DOI:10.1210/endo-117-5-1996 |
|
|